Report cover image

Global Biosimilar Market Outlook and Growth Opportunities 2025

Publisher APO Research, Inc.
Published Aug 16, 2025
Length 196 Pages
SKU # APRC20359501

Description

Summary

According to APO Research, the global Biosimilar market is projected to grow from US$ million in 2025 to US$ million by 2031, at a compound annual growth rate (CAGR) of % during the forecast period.

The North American market for Biosimilar is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % from 2025 through 2031.

The Asia-Pacific market for Biosimilar is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

In China, the Biosimilar market is expected to rise from $ million to $ million by 2031, at a CAGR of I% from 2025 through 2031.

The Europe market for Biosimilar is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Major global companies in the Biosimilar market include Bio-Thera, Shanghai Henlius, Gan&Lee, Jiangsu Hengrui, United Laboratory, Luye Pharma, Qilu Pharmaceutical, 3SBIO and Tonghua Dongbao, etc. In 2024, the top three vendors accounted for approximately % of the market revenue.

This report presents an overview of global market for Biosimilar, revenue and gross margin. Analyses of the global market trends, with historic market revenue for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.

This report researches the key producers of Biosimilar, also provides the value of main regions and countries. Of the upcoming market potential for Biosimilar, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Biosimilar revenue, market share and industry ranking of main companies, data from 2020 to 2025. Identification of the major stakeholders in the global Biosimilar market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
All companies have demonstrated varying levels of sales growth and profitability over the past six years, while some companies have experienced consistent growth, others have shown fluctuations in performance. The overall trend suggests a positive outlook for the global Biosimilar company landscape, with companies adapting to market dynamics and maintaining profitability amidst changing conditions.
Biosimilar Segment by Company

Bio-Thera
Shanghai Henlius
Gan&Lee
Jiangsu Hengrui
United Laboratory
Luye Pharma
Qilu Pharmaceutical
3SBIO
Tonghua Dongbao
Innovent Biologics
Zhejiang Hisun
Biosimilar Segment by Type

Biosimilar Monoclonal Antibodies
Biosimilar Insulin
Others
Biosimilar Segment by Application

Diabetes
Immunological Diseases
Cancer
Others
Biosimilar Segment by Region

North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE

Study Objectives

1. To analyze and research the global Biosimilar status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the Biosimilar key companies, revenue, market share, and recent developments.
3. To split the Biosimilar breakdown data by regions, type, companies, and application.
4. To analyze the global and key regions Biosimilar market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Biosimilar significant trends, drivers, influence factors in global and regions.
6. To analyze Biosimilar competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Biosimilar market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Biosimilar and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Biosimilar.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Biosimilar industry.
Chapter 3: Detailed analysis of Biosimilar company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales value of Biosimilar in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.
Chapter 7: Sales value of Biosimilar in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 9: Concluding Insights.

Table of Contents

196 Pages
1 Market Overview
1.1 Product Definition
1.2 Global Biosimilar Market Size, 2020 VS 2024 VS 2031
1.3 Global Biosimilar Market Size (2020-2031)
1.4 Assumptions and Limitations
1.5 Study Goals and Objectives
2 Biosimilar Market Dynamics
2.1 Biosimilar Industry Trends
2.2 Biosimilar Industry Drivers
2.3 Biosimilar Industry Opportunities and Challenges
2.4 Biosimilar Industry Restraints
3 Biosimilar Market by Company
3.1 Global Biosimilar Company Revenue Ranking in 2024
3.2 Global Biosimilar Revenue by Company (2020-2025)
3.3 Global Biosimilar Company Ranking (2023-2025)
3.4 Global Biosimilar Company Manufacturing Base and Headquarters
3.5 Global Biosimilar Company Product Type and Application
3.6 Global Biosimilar Company Establishment Date
3.7 Market Competitive Analysis
3.7.1 Global Biosimilar Market Concentration Ratio (CR5 and HHI)
3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2024
3.7.3 2024 Biosimilar Tier 1, Tier 2, and Tier 3 Companies
3.8 Mergers and Acquisitions Expansion
4 Biosimilar Market by Type
4.1 Biosimilar Type Introduction
4.1.1 Biosimilar Monoclonal Antibodies
4.1.2 Biosimilar Insulin
4.1.3 Others
4.2 Global Biosimilar Sales Value by Type
4.2.1 Global Biosimilar Sales Value by Type (2020 VS 2024 VS 2031)
4.2.2 Global Biosimilar Sales Value by Type (2020-2031)
4.2.3 Global Biosimilar Sales Value Share by Type (2020-2031)
5 Biosimilar Market by Application
5.1 Biosimilar Application Introduction
5.1.1 Diabetes
5.1.2 Immunological Diseases
5.1.3 Cancer
5.1.4 Others
5.2 Global Biosimilar Sales Value by Application
5.2.1 Global Biosimilar Sales Value by Application (2020 VS 2024 VS 2031)
5.2.2 Global Biosimilar Sales Value by Application (2020-2031)
5.2.3 Global Biosimilar Sales Value Share by Application (2020-2031)
6 Biosimilar Regional Value Analysis
6.1 Global Biosimilar Sales Value by Region: 2020 VS 2024 VS 2031
6.2 Global Biosimilar Sales Value by Region (2020-2031)
6.2.1 Global Biosimilar Sales Value by Region: 2020-2025
6.2.2 Global Biosimilar Sales Value by Region (2026-2031)
6.3 North America
6.3.1 North America Biosimilar Sales Value (2020-2031)
6.3.2 North America Biosimilar Sales Value Share by Country, 2024 VS 2031
6.4 Europe
6.4.1 Europe Biosimilar Sales Value (2020-2031)
6.4.2 Europe Biosimilar Sales Value Share by Country, 2024 VS 2031
6.5 Asia-Pacific
6.5.1 Asia-Pacific Biosimilar Sales Value (2020-2031)
6.5.2 Asia-Pacific Biosimilar Sales Value Share by Country, 2024 VS 2031
6.6 South America
6.6.1 South America Biosimilar Sales Value (2020-2031)
6.6.2 South America Biosimilar Sales Value Share by Country, 2024 VS 2031
6.7 Middle East & Africa
6.7.1 Middle East & Africa Biosimilar Sales Value (2020-2031)
6.7.2 Middle East & Africa Biosimilar Sales Value Share by Country, 2024 VS 2031
7 Biosimilar Country-level Value Analysis
7.1 Global Biosimilar Sales Value by Country: 2020 VS 2024 VS 2031
7.2 Global Biosimilar Sales Value by Country (2020-2031)
7.2.1 Global Biosimilar Sales Value by Country (2020-2025)
7.2.2 Global Biosimilar Sales Value by Country (2026-2031)
7.3 USA
7.3.1 USA Biosimilar Sales Value Growth Rate (2020-2031)
7.3.2 USA Biosimilar Sales Value Share by Type, 2024 VS 2031
7.3.3 USA Biosimilar Sales Value Share by Application, 2024 VS 2031
7.4 Canada
7.4.1 Canada Biosimilar Sales Value Growth Rate (2020-2031)
7.4.2 Canada Biosimilar Sales Value Share by Type, 2024 VS 2031
7.4.3 Canada Biosimilar Sales Value Share by Application, 2024 VS 2031
7.5 Mexico
7.5.1 Mexico Biosimilar Sales Value Growth Rate (2020-2031)
7.5.2 Mexico Biosimilar Sales Value Share by Type, 2024 VS 2031
7.5.3 Mexico Biosimilar Sales Value Share by Application, 2024 VS 2031
7.6 Germany
7.6.1 Germany Biosimilar Sales Value Growth Rate (2020-2031)
7.6.2 Germany Biosimilar Sales Value Share by Type, 2024 VS 2031
7.6.3 Germany Biosimilar Sales Value Share by Application, 2024 VS 2031
7.7 France
7.7.1 France Biosimilar Sales Value Growth Rate (2020-2031)
7.7.2 France Biosimilar Sales Value Share by Type, 2024 VS 2031
7.7.3 France Biosimilar Sales Value Share by Application, 2024 VS 2031
7.8 U.K.
7.8.1 U.K. Biosimilar Sales Value Growth Rate (2020-2031)
7.8.2 U.K. Biosimilar Sales Value Share by Type, 2024 VS 2031
7.8.3 U.K. Biosimilar Sales Value Share by Application, 2024 VS 2031
7.9 Italy
7.9.1 Italy Biosimilar Sales Value Growth Rate (2020-2031)
7.9.2 Italy Biosimilar Sales Value Share by Type, 2024 VS 2031
7.9.3 Italy Biosimilar Sales Value Share by Application, 2024 VS 2031
7.10 Spain
7.10.1 Spain Biosimilar Sales Value Growth Rate (2020-2031)
7.10.2 Spain Biosimilar Sales Value Share by Type, 2024 VS 2031
7.10.3 Spain Biosimilar Sales Value Share by Application, 2024 VS 2031
7.11 Russia
7.11.1 Russia Biosimilar Sales Value Growth Rate (2020-2031)
7.11.2 Russia Biosimilar Sales Value Share by Type, 2024 VS 2031
7.11.3 Russia Biosimilar Sales Value Share by Application, 2024 VS 2031
7.12 Netherlands
7.12.1 Netherlands Biosimilar Sales Value Growth Rate (2020-2031)
7.12.2 Netherlands Biosimilar Sales Value Share by Type, 2024 VS 2031
7.12.3 Netherlands Biosimilar Sales Value Share by Application, 2024 VS 2031
7.13 Nordic Countries
7.13.1 Nordic Countries Biosimilar Sales Value Growth Rate (2020-2031)
7.13.2 Nordic Countries Biosimilar Sales Value Share by Type, 2024 VS 2031
7.13.3 Nordic Countries Biosimilar Sales Value Share by Application, 2024 VS 2031
7.14 China
7.14.1 China Biosimilar Sales Value Growth Rate (2020-2031)
7.14.2 China Biosimilar Sales Value Share by Type, 2024 VS 2031
7.14.3 China Biosimilar Sales Value Share by Application, 2024 VS 2031
7.15 Japan
7.15.1 Japan Biosimilar Sales Value Growth Rate (2020-2031)
7.15.2 Japan Biosimilar Sales Value Share by Type, 2024 VS 2031
7.15.3 Japan Biosimilar Sales Value Share by Application, 2024 VS 2031
7.16 South Korea
7.16.1 South Korea Biosimilar Sales Value Growth Rate (2020-2031)
7.16.2 South Korea Biosimilar Sales Value Share by Type, 2024 VS 2031
7.16.3 South Korea Biosimilar Sales Value Share by Application, 2024 VS 2031
7.17 India
7.17.1 India Biosimilar Sales Value Growth Rate (2020-2031)
7.17.2 India Biosimilar Sales Value Share by Type, 2024 VS 2031
7.17.3 India Biosimilar Sales Value Share by Application, 2024 VS 2031
7.18 Australia
7.18.1 Australia Biosimilar Sales Value Growth Rate (2020-2031)
7.18.2 Australia Biosimilar Sales Value Share by Type, 2024 VS 2031
7.18.3 Australia Biosimilar Sales Value Share by Application, 2024 VS 2031
7.19 Southeast Asia
7.19.1 Southeast Asia Biosimilar Sales Value Growth Rate (2020-2031)
7.19.2 Southeast Asia Biosimilar Sales Value Share by Type, 2024 VS 2031
7.19.3 Southeast Asia Biosimilar Sales Value Share by Application, 2024 VS 2031
7.20 Brazil
7.20.1 Brazil Biosimilar Sales Value Growth Rate (2020-2031)
7.20.2 Brazil Biosimilar Sales Value Share by Type, 2024 VS 2031
7.20.3 Brazil Biosimilar Sales Value Share by Application, 2024 VS 2031
7.21 Argentina
7.21.1 Argentina Biosimilar Sales Value Growth Rate (2020-2031)
7.21.2 Argentina Biosimilar Sales Value Share by Type, 2024 VS 2031
7.21.3 Argentina Biosimilar Sales Value Share by Application, 2024 VS 2031
7.22 Chile
7.22.1 Chile Biosimilar Sales Value Growth Rate (2020-2031)
7.22.2 Chile Biosimilar Sales Value Share by Type, 2024 VS 2031
7.22.3 Chile Biosimilar Sales Value Share by Application, 2024 VS 2031
7.23 Colombia
7.23.1 Colombia Biosimilar Sales Value Growth Rate (2020-2031)
7.23.2 Colombia Biosimilar Sales Value Share by Type, 2024 VS 2031
7.23.3 Colombia Biosimilar Sales Value Share by Application, 2024 VS 2031
7.24 Peru
7.24.1 Peru Biosimilar Sales Value Growth Rate (2020-2031)
7.24.2 Peru Biosimilar Sales Value Share by Type, 2024 VS 2031
7.24.3 Peru Biosimilar Sales Value Share by Application, 2024 VS 2031
7.25 Saudi Arabia
7.25.1 Saudi Arabia Biosimilar Sales Value Growth Rate (2020-2031)
7.25.2 Saudi Arabia Biosimilar Sales Value Share by Type, 2024 VS 2031
7.25.3 Saudi Arabia Biosimilar Sales Value Share by Application, 2024 VS 2031
7.26 Israel
7.26.1 Israel Biosimilar Sales Value Growth Rate (2020-2031)
7.26.2 Israel Biosimilar Sales Value Share by Type, 2024 VS 2031
7.26.3 Israel Biosimilar Sales Value Share by Application, 2024 VS 2031
7.27 UAE
7.27.1 UAE Biosimilar Sales Value Growth Rate (2020-2031)
7.27.2 UAE Biosimilar Sales Value Share by Type, 2024 VS 2031
7.27.3 UAE Biosimilar Sales Value Share by Application, 2024 VS 2031
7.28 Turkey
7.28.1 Turkey Biosimilar Sales Value Growth Rate (2020-2031)
7.28.2 Turkey Biosimilar Sales Value Share by Type, 2024 VS 2031
7.28.3 Turkey Biosimilar Sales Value Share by Application, 2024 VS 2031
7.29 Iran
7.29.1 Iran Biosimilar Sales Value Growth Rate (2020-2031)
7.29.2 Iran Biosimilar Sales Value Share by Type, 2024 VS 2031
7.29.3 Iran Biosimilar Sales Value Share by Application, 2024 VS 2031
7.30 Egypt
7.30.1 Egypt Biosimilar Sales Value Growth Rate (2020-2031)
7.30.2 Egypt Biosimilar Sales Value Share by Type, 2024 VS 2031
7.30.3 Egypt Biosimilar Sales Value Share by Application, 2024 VS 2031
8 Company Profiles
8.1 Bio-Thera
8.1.1 Bio-Thera Comapny Information
8.1.2 Bio-Thera Business Overview
8.1.3 Bio-Thera Biosimilar Revenue and Gross Margin (2020-2025)
8.1.4 Bio-Thera Biosimilar Product Portfolio
8.1.5 Bio-Thera Recent Developments
8.2 Shanghai Henlius
8.2.1 Shanghai Henlius Comapny Information
8.2.2 Shanghai Henlius Business Overview
8.2.3 Shanghai Henlius Biosimilar Revenue and Gross Margin (2020-2025)
8.2.4 Shanghai Henlius Biosimilar Product Portfolio
8.2.5 Shanghai Henlius Recent Developments
8.3 Gan&Lee
8.3.1 Gan&Lee Comapny Information
8.3.2 Gan&Lee Business Overview
8.3.3 Gan&Lee Biosimilar Revenue and Gross Margin (2020-2025)
8.3.4 Gan&Lee Biosimilar Product Portfolio
8.3.5 Gan&Lee Recent Developments
8.4 Jiangsu Hengrui
8.4.1 Jiangsu Hengrui Comapny Information
8.4.2 Jiangsu Hengrui Business Overview
8.4.3 Jiangsu Hengrui Biosimilar Revenue and Gross Margin (2020-2025)
8.4.4 Jiangsu Hengrui Biosimilar Product Portfolio
8.4.5 Jiangsu Hengrui Recent Developments
8.5 United Laboratory
8.5.1 United Laboratory Comapny Information
8.5.2 United Laboratory Business Overview
8.5.3 United Laboratory Biosimilar Revenue and Gross Margin (2020-2025)
8.5.4 United Laboratory Biosimilar Product Portfolio
8.5.5 United Laboratory Recent Developments
8.6 Luye Pharma
8.6.1 Luye Pharma Comapny Information
8.6.2 Luye Pharma Business Overview
8.6.3 Luye Pharma Biosimilar Revenue and Gross Margin (2020-2025)
8.6.4 Luye Pharma Biosimilar Product Portfolio
8.6.5 Luye Pharma Recent Developments
8.7 Qilu Pharmaceutical
8.7.1 Qilu Pharmaceutical Comapny Information
8.7.2 Qilu Pharmaceutical Business Overview
8.7.3 Qilu Pharmaceutical Biosimilar Revenue and Gross Margin (2020-2025)
8.7.4 Qilu Pharmaceutical Biosimilar Product Portfolio
8.7.5 Qilu Pharmaceutical Recent Developments
8.8 3SBIO
8.8.1 3SBIO Comapny Information
8.8.2 3SBIO Business Overview
8.8.3 3SBIO Biosimilar Revenue and Gross Margin (2020-2025)
8.8.4 3SBIO Biosimilar Product Portfolio
8.8.5 3SBIO Recent Developments
8.9 Tonghua Dongbao
8.9.1 Tonghua Dongbao Comapny Information
8.9.2 Tonghua Dongbao Business Overview
8.9.3 Tonghua Dongbao Biosimilar Revenue and Gross Margin (2020-2025)
8.9.4 Tonghua Dongbao Biosimilar Product Portfolio
8.9.5 Tonghua Dongbao Recent Developments
8.10 Innovent Biologics
8.10.1 Innovent Biologics Comapny Information
8.10.2 Innovent Biologics Business Overview
8.10.3 Innovent Biologics Biosimilar Revenue and Gross Margin (2020-2025)
8.10.4 Innovent Biologics Biosimilar Product Portfolio
8.10.5 Innovent Biologics Recent Developments
8.11 Zhejiang Hisun
8.11.1 Zhejiang Hisun Comapny Information
8.11.2 Zhejiang Hisun Business Overview
8.11.3 Zhejiang Hisun Biosimilar Revenue and Gross Margin (2020-2025)
8.11.4 Zhejiang Hisun Biosimilar Product Portfolio
8.11.5 Zhejiang Hisun Recent Developments
9 Concluding Insights
10 Appendix
10.1 Reasons for Doing This Study
10.2 Research Methodology
10.3 Research Process
10.4 Authors List of This Report
10.5 Data Source
10.5.1 Secondary Sources
10.5.2 Primary Sources
How Do Licenses Work?
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.